Panelists including Amit R. Majithia, MD, presented new opportunities and approaches to quantify and understand insulin resistance in diverse populations. Genome-wide association studies are among the tools that can tease out the genetic basis of metabolic responses. Read more

While current guidelines have limited data on the use of non-insulin therapies for patients with diabetes who are hospitalized, several randomized trials are focusing on the use of incretin-based therapy for this patient population, Smita Kumar, MD, explained at the 82nd Scientific Sessions. Read more

Patient fatigue with counting carbs and consuming high-protein snacks may drive interest in exploring dietary alternatives for type 2 diabetes management. Krista A. Varaday, PhD, discussed the effects of intermittent fasting and exercise on fasting insulin, insulin resistance, and insulin sensitivity, as well as the barriers to patient adherence to time-restricted eating. Read more

Loss of beta cell function happens abruptly around the time of type 1 diabetes onset, noted panelist Matthias von Herrath, MD, though many individuals with long-standing type 1 diabetes retain beta cell mass and some degree of beta cell function. Hallmarks of progression include upregulation of major histocompatibility complexes and the appearance of CD8-positive T-cells in islets. Read more

Among the available screening tools for type 1 diabetes, autoantibody testing can identify people who are in the early stages of the disease and are at high risk of developing clinical type 1 diabetes, providing a window of opportunity for early intervention and potentially preventing diabetic ketoacidosis, explained Chantal Mathieu, MD, PhD. Read more

Investigators found that three of the subphenotypes have increased glycemia, but only individuals in two clusters have imminent diabetes risks, explained Robert Wagner, MD. By contrast, they found another cluster of individuals with prediabetes who have only moderate risk of type 2 diabetes but an increased risk of kidney disease and all-cause mortality. Read more

Raja Kandaswamy, MD, reviewed indications and recent outcomes of pancreas transplant alone and simultaneous pancreas-kidney transplant in patients with type 1 and type 2 diabetes. Simultaneous transplants have excellent short- and long-term results, but long-term results of solitary pancreas transplants need to improve, he said. Read more

Little is known about the impact of low-calorie sweeteners on taste preferences, insulin secretion, adipogenesis, the gut microbiome, glucose absorption, and the risk of cardiometabolic disease, according to Michelle Pang, BSc. One reason for that is that they are structured differently but are often studied together, resulting in conflicting findings. Read more

An analysis of Diabetes Control and Complications Trial data, as well as a number of cross-sectional and longitudinal studies, provide evidence supporting the association between time in range and microvascular complications, cardiovascular disease, and mortality, according to Roy Beck, MD, PhD. Read more

Exercise management is trial and error and always will be as long as exogenous insulin is being manipulated, according to Laurel Messer, PhD, RN, CDCES, one of four experts who shared several clinical pearls in the practical use of automated insulin delivery systems. Read more

Insulin availability is a challenge across the globe, particularly in many lower- and middle-income countries. Panelists including Sylvia Kehlenbrink, MD, outlined the breadth of this obstacle to diabetes care and potential national and international strategies for overcoming it. Read more

To identify ways to help older adults increase their use of diabetes technology, several factors must be taken into consideration at each level of care, including systemic, clinician, personal caregiver, and patient factors. “The thing with technology is that you have the shoe, but it must fit for the right outcome,” said Medha Munshi, MD. Read more

Eda Cengiz, MD, MHS, who reviewed some of the most recent technological advances in diabetes care and management, said the most exciting development in this area has been automated insulin delivery, also known as artificial pancreas, hybrid closed-loop system, or bionic pancreas. Read more

Therapeutic inertia does not have a single cause. Clinician-, patient-, and systematic-related factors all contribute, said Christine Beebe, MS. Meta-analysis indicates that diabetes management programs should be set up to treat patients while taking into consideration different clinician types, clinic settings, and patient communications for optimal effectiveness. Read more

Expectant mothers who exercise have greater levels of docosahexaenoic acid (DHA) in late pregnancy than those who do not, explained Linda May, PhD, MS, FAHA. DHA helps mothers deliver on time, is good for placentas, helps control the mother’s lipids, and is essential for the baby’s growth and development. Read more

In a report to Congress earlier this year, the National Clinical Care Commission (NCCC) outlined more than three dozen recommendations for a national effort across multiple agencies and levels of government to address social determinants in the pathogenesis and progression of diabetes. NCCC Chair William H. Herman, MD, MPH, and other Commission members highlighted their recommendations at the 82nd Scientific Sessions. Read more

Carol H. Wysham, MD, says there is serious therapeutic inertia at play as patients often remain in poor glycemic control for more than seven years before intensification of treatment. Yet repeated studies show that up-titrating GLP-1 receptor agonist dosing improves glycemic outcomes as well as loss and maintenance of weight. Read more

Obesity can lead to insulin resistance, which sets the stage for the development of beta amyloid plaques and tau tangles in the brain, both hallmarks of Alzheimer’s disease. Some early trials of inhaled insulin in people with type 2 diabetes show improved memory, Auriel A. Willette, PhD, MS, and Vera Novak, MD, PhD, explained. Read more

An expert panel including Paul McGuigan, RN, CDCES, stressed that creating a continuum of care and support starting in high school, including promoting health insurance literacy, is key to setting up young people with type 2 diabetes to successfully manage their disease as they transition to adulthood. Read more

Afternoon training improves glucose sensitivity, increases fat loss, and increases work performance while reducing nocturnal blood glucose levels, said Juleen R. Zierath, PhD, one of the panelists discussing the molecular mechanisms known to affect the circadian rhythms of liver function. Read more

A distinguished panel of experts reviewed the latest information on the development of weekly insulins, oral insulins, glucose-sensitive insulin, and the role of biosimilars and interchangeable insulins on Monday, June 6. Michael A. Weiss, MD, PhD, MBA, discussed the development of glucose-sensitive insulin, or “smart insulin,” that can be activated through the use of a synthetic “switch” that can be opened or closed using a simple sugar sensor. Read more

Four weight loss researchers discussed the value of behavioral therapy, intensive lifestyle interventions, and pharmacotherapy during a Scientific Sessions symposium on Sunday, June 5. “There’s quite a bit of evidence showing that individuals who self-monitor over time generally are the best in terms of maintenance of behaviors and weight,” said Hollie Raynor, PhD, RD, LDN. Read more

An expert panel examined several barriers limiting the use of diabetes technology in under-resourced communities at the 82nd Scientific Sessions. “Regardless of their socioeconomic status, everyone deserves access to the right technology at the right time, especially in a chronic condition like diabetes,” said Vivian N. Ayuk, PharmD, CDCES. Read more

A panel of clinical leaders discussed the importance of educating hospital staff about diabetes management and care during a Scientific Sessions symposium on Monday, June 6. “It really does affect the patient experience when we don’t do an excellent job managing their glycemia, and that’s the point of education,” said Leigh B. Bak, MSN, APRN, ACNS-BC, CDCES. Read more

Racial, ethnic, and socioeconomic disparities that limit access to diabetes medications and technologies lead to poor glycemic control, diabetic emergencies, and adverse cardiovascular outcomes, according to Sara Jane Cromer, MD, one of three presenters in a symposium on Monday, June 6, that examined disparities in the use of diabetes medications and technologies. Read more

After SURMOUNT-1 trial results were reported at the Scientific Sessions on Saturday and made worldwide headlines, a special session on Tuesday, June 7, will showcase more than 20 tirzepatide abstracts presented over the five days of the meeting. “Attendees are seeing and hearing data that is being presented for the first time here in New Orleans,” said Katherine R. Tuttle, MD, FASN, FACP, FNKF, one of the session’s presenters. Read more

Genomic analysis, single-cell sequencing, and epigenomic approaches are uncovering new mechanisms in the development and progression of diabetic kidney disease. A panel of researchers, including Jose C. Florez, MD, PhD, will provide an update on the latest discoveries. Read more

Richard David Leslie, MBBS, MRCS, MD, FRCP, FAoP, says diabetes should be rethought. He will open a unique symposium on the final day of the 82nd Scientific Sessions that will examine various aspects of heterogeneity in diabetes. Read more

Three neurological researchers—Auriel Willette, PhD, Vera Novak, MD, PhD, and Valory Pavlik, PhD (left to right)—will discuss the links between diabetes and cognitive decline and explore possible interventions during a Scientific Sessions symposium on Tuesday, June, 7. Read more

Once thought of as nonfunctional vestigial relics of evolutionary history, cilia are emerging as critical components in multiple signaling pathways that control sight, smell, renal function, feeding behavior and obesity, skeletal formation, and, most recently, insulin secretion and glucose homeostasis. “Cilia biology is going to explode in diabetes,” predicts Jing Hughes, MD, PhD. Read more

Four researchers, including Dongyin Guan, PhD (left), Kristin Eckel-Mahan, PhD, will discuss how circadian misalignment impacts metabolic health during a Scientific Sessions symposium on Tuesday, June 7. Read more

Frances M. Ashcroft, DBE, FRS, FMedSci, recipient of the ADA’s 2022 Banting Medal for Scientific Achievement, discussed a novel approach—inhibiting glucokinase activity to improve insulin secretion—for treating type 2 diabetes during her award lecture on Sunday, June 5. Read more

Linda DiMeglio, MD, MPH, David A. D’Alessio, MD, and Silvia Corvera, MD (left to right), reviewed some of the key advances in diabetes research and care during the annual Year in Review session. Read more

The recent emergence of effective anti-obesity medications raises the question of whether weight loss, rather than glucose control, should be considered the primary target for intervention in type 2 diabetes. Ildiko Lingvay, MD, MPH, MSCS, and Jeffrey I. Mechanick, MD, debated that question at the 82nd Scientific Sessions. Read more

Five behavioral health specialists discussed the effects of stigma in diabetes care during an afternoon symposium on Saturday, June 4. Alan M. Delamater, PhD, opened the symposium by recounting his 40-year journey in behavioral diabetes research as he presented the annual Richard R. Rubin Award Lecture. Read more

Losing weight, no matter how much or how little, has health benefits for obese people with type 2 diabetes. And the more they lose, the better the outcome, said Priya Sumithran, PhD, one of three panelists in a Scientific Session symposium that explored the use of lifestyle interventions, bariatric surgery, and pharmacotherapy to manage obesity and type 2 diabetes. Read more

Research examining central nervous system control of systemic metabolism suggests that the CNS plays an important, and perhaps a dominant role in the pathogenesis and progression of at least some forms of diabetes. Four leaders in the field, including Vincent Prevot, PhD, and Sarah Stanley, MB, BCh, PhD, will review the latest findings at the Scientific Sessions. Read more

Cardiovascular disease is recognized as one of the most common complications of diabetes. Clinicians have long viewed coronary arterial disease and atherosclerosis as the major culprits, but heart failure has emerged as a larger problem—and one that’s more difficult to manage, according to Rong Tian, MD, PhD. Read more

Four cardiologists, including Yi Tan, PhD (left), and Harold E. Bays, MD, will discuss the underlying mechanisms, diagnosis, and treatment of cardiomyopathy, a familiar yet underappreciated complication of diabetes. “My sense is we are on the cusp of some really interesting times in cardiomyopathy in diabetes,” Dr. Bays said. Read more

Otis W. Kirksey, PharmD, RPh, CDCES, BC-ADM, ADA President, Health Care & Education, discussed his dedication to the diabetes community on Saturday, June 4, saying that improving the lives of people with diabetes takes equal parts of dedication and hard work. Read more

Amy Hess-Fischl, MS, RDN, LDN, BC-ADM, CDCES, received the ADA’s 2022 Outstanding Educator in Diabetes Award at the 82nd Scientific Sessions. Diabetes self-management education and support (DSMES) should be the standard-of-care for every person with diabetes, she said. Read more

Davida F. Kruger, MSN, APN-BC, BC-ADM, told women at the Saturday afternoon symposium that if they’re not invited to the table, show up anyway—with a chair. And keep moving that chair closer and closer to the table. Read more

Physical activity is an integral part of the diabetes management toolbox, but not everyone responds to physical activity the same way or has the ability to exercise regularly. A panel of exercise scientists, including Carlos Crespo, PhD, examined how health disparities and sex differences impact physical activity during a morning symposium on Saturday, June 4. Read more

During an afternoon symposium on Friday, June 3, a diverse interprofessional panel of experts—including an epidemiologist, a health services researcher, a historian, and a medical anthropologist—shared their work and insights on the role of race and racism in diabetes research and diabetes care. “Implicit bias training alone does not work in terms of being sustainable. It has to be accompanied by systemic structural interventions—they go hand in hand,” said Marshall Chin, MD, MPH. Read more

Four experts, including Satish K. Garg, MD, and Holly Willis, PhD, RDN, CDCES, will discuss practical strategies to improve eating habits and optimize the growing number of insulin-dosing options to improve glucose control, increase time in range, reduce A1C, and lower the risk of long-term complications from poor glucose control. Read more

Jamie Feldman, MD, will chair a Scientific Sessions symposium examining diabetes, metabolic health, and clinical care among people who are lesbian, gay, bisexual, transgender, gender diverse, queer, or questioning. Read more

During a Friday afternoon session, an interprofessional panel of experts provided their perspectives and reviewed some of the most current literature on improving outcomes across the cardio-renal-metabolic spectrum of diabetes. “In the tsunami of diabetes, multidisciplinary, interdisciplinary therapy is essential if we are going to continue to improve outcomes,” said Neda Rasouli, MD. Read more

Alison Evert, MS, RDN, CDCES (left), and Maureen Chomko, RD, CDCES, addressed several nutrition controversies—from net carbs to fad diets to meal and snack frequency—during a mini-symposium on the first day of the 82nd Scientific Sessions. Read more

Amy Hess-Fischl, MS, RDN, LDN, BC-ADM, CDCES (left), and Michelle F. Magee, MD, MB, BCh, LRCPSI, will review the updated national standards for diabetes self-management education and support. A companion session will outline the revised certification program for certified diabetes care and education specialists. Read more

The ADA and the European Association for the Study of Diabetes published a consensus report on precision diabetes medicine in 2020. Scientific Sessions attendees will get an update on this joint initiative during a special symposium on Saturday, June 4. John M. Dennis, PhD (left), and David Kerr, MD, are two of the featured presenters. Read more

James D. Johnson, PhD (left), and Steven E. Kahn, MB, ChB, debated whether hyperinsulinemia is the primary defect that results in type 2 diabetes during a mini-symposium on Friday, June 3. “The big question is whether insulin resistance is primary or if hyperinsulinemia stimulates insulin resistance,” Dr. Johnson said. Read more

Amy K. Mottl, MD, MPH, FASN, will open the joint session, which brings together experts from various disciplines in an effort to improve screening, uptake of practice guidelines, and patient outcomes. Read more

The mental health burden of diabetes remains “grossly underappreciated,” according to Katharine Barnard, PhD. She and other experts will discuss strategies to identify and provide support to diabetes patients at risk for suicide and self-harm. Read more

Hollie Raynor, PhD, RD, and three other expert presenters will review the latest lessons learned for maximizing weight loss maintenance in the U.S. National Diabetes Prevention Program. Read more

Person-centered care involves working with diabetes patients to determine the best treatment approaches to fit their lives. The best evidence and clinical guidelines don’t work for all individuals, according to Katherine S. O’Neal, PharmD, MBA, BCACP, CDCES, BC-ADM, CLS, FADCES. Read more

A multidisciplinary panel including diabetes care and education specialists Jasmine D. Gonzalvo, PharmD, CDCES, BC-ADM (left), and Vivian N. Ayuk, PharmD, CDCES, will discuss educational strategies to help underserved populations overcome barriers to technology access. Read more

Factors such as sex, gender, age, ethnicity, education, and living environment affect a person's physical activity. Jane E. Yardley, PhD, and three other experts will share strategies for prescribing physical activity that are feasible and sustainable for various patient groups. Read more

The American Diabetes Association is pulling back the curtain on its annual updates to the ADA Standards of Care at the 82nd Scientific Sessions. “We will share how we work with new data that have been published recently to adjust the standards,” said Vanita R. Aroda, MD, a member of the ADA Professional Practice Committee. Read more

"Heart failure has been a forgotten disorder because the basic and translational science models were created with atherosclerosis in diabetes leading to ischemic heart attacks and strokes. But if you look at the real world, people with diabetes develop heart failure and their mortality is horrific,” said Eldrin F. Lewis, MD, MPH. Read more

Two symposia on the first day of the Scientific Sessions will review the latest findings and new treatment strategies to mitigate cardiac and kidney disease in diabetes. “Our patients cross the boundaries between cardiology and diabetes, and we have to do the same to co-manage them more effectively,” said Suzanne V. Arnold, MD, MHA. Read more

“What’s unique about these new classes of drugs is that they’re not glucose-lowering drugs. They’re cardio-renal risk-reducing agents that happen to lower glucose if your kidney function is normal or reasonable,” said George Bakris, MD. Read more

Despite its negative impact on quality of life, diabetic peripheral neuropathy (DPN) remains undertreated, with only half of individuals receiving analgesic treatment and only 28% of them using anticonvulsants or antidepressants, according to Loretta Vileikyte, MD, PhD (left), who will discuss the psychosocial impact of painful DPN. Stephanie Eid, PhD, will discuss efforts to develop mechanism-based therapies that impact peripheral neuropathy before irreversible nerve damage occurs. Read more

There’s a lot of misinformation and conflicting advice about healthy eating habits. Maureen Chomko, RD, CDCES, and Alison Evert, MS, RDN, CDCES, will help Scientific Sessions attendees clear up the confusion so they can have quality conversations about nutrition with their patients. Read more

The ADA and the European Association for the Study of Diabetes will release the latest consensus recommendations on managing hyperglycemia in type 2 diabetes during a special joint session co-chaired by ADA Chief Scientific and Medical Officer Robert A. Gabbay, MD, PhD (left), and EASD President Stefano Del Prato, MD. Read more

Five diabetes researchers, including Luis A. Rodriguez, PhD, MPH, RD, and Deborah A. Ellis, PhD, will discuss how translational science is being used to promote health equity and address social determinants of health in diabetes prevention and care on the first day of the Scientific Sessions. Read more

The bionic pancreas, a system that mimics the natural pancreatic regulation of serum glucose by automatically dosing insulin and glucagon, has been a dream for decades. New research to be presented at the Scientific Sessions could reveal whether that dream is one step closer to reality, according to Roy W. Beck, MD, PhD. Read more

Linda A. DiMeglio, MD, MPH, David A. D’Alessio, MD, and Silvia Corvera, MD, will summarize a year’s worth of discovery, innovation, and paradigm shifts in diabetes research and care during the annual Year in Review, one of the most popular presentations each year at the Scientific Sessions. Read more

Four diabetes care and education specialists, including Paul McGuigan, RN, CDCES, and Julia E. Blanchette, PhD, RN, BC-ADM, CDCES, will discuss both time-tested and novel approaches to improve the quality-of-life of young people living with diabetes. Read more

A1C is routinely used to monitor glycemic control for patients with diabetes. At the Scientific Sessions, Jay H. Shubrook, DO, FACOFP, FAAFP, BC-ADM, and David B. Sacks, MB ChB, FACP, FRCPath, debated whether point-of-care A1C should be part of the diagnostic toolkit for diabetes. Read more

Marcela Brissova, PhD, Struan F.A. Grant, PhD, Maggie Ng, PhD, and Melina Claussnitzer, PhD, discussed how molecular and genetic studies are providing new insight into the influence of genetics in the development and progression of diabetes. Read more

“The KPMP is all about using the kidney biopsy, which is an old tool, to understand kidney disease in a new way by almost turbocharging the information that we get,” said Jonathan Himmelfarb, MD. Read more

New research uses single-cell technologies to explore the roles of adipocytes, macrophages, beta cells, and fibroblast growth factor-1 in metabolic tissue function. Qiong (Annabel) Wang, PhD, Christopher K. Glass, MD, PhD, Heiko Lickert, PhD, and Michael W. Schwartz, MD, reviewed this work at the Scientific Sessions. Read more

Brian A. Ference, MD, MPhil, MSc, FACC, FESC, Lisa R. Tannock, MD, Jean-Claude Tardif, CM, MD, FRCPC, FCCS, FACC, FAHA, FESC, FCAHS, and Stephen G. Young, MD, discussed new insights into the role of triglycerides in cardiovascular disease at the Scientific Sessions. Read more

A symposium sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases showcased current research by six young scientists—Emily K. Sims, MD, Emilyn U. Alejandro, PhD, Rafael Arrojo e Drigo, PhD, Camille E. Powe, MD, Rochelle N. Naylor, MD, and Joshua J. Joseph, MD, MPH, FAHA—aimed at developing a more stratified medical approach to diabetes from the bench to bedside. Read more

Patients have rallied behind the development of do-it-yourself automated insulin delivery systems to manage their diabetes. Natalie J. Bellini, MSN, FNP-BC, Dana Lewis, BA, Anna Norton, MS, and David M. Maahs, MD, PhD, discussed potential ramifications for patients, clinicians, researchers, and even manufacturers of commercial closed-loop devices. Read more

“Equity is our goal,” said Tiffany L. Gary-Webb, PhD, MHS. “But the reality is right now we’re not anywhere near that. The reality is that some people have much more than they need and there are other people who are digging themselves out of a hole.” Read more

Jonathan Z. Long, PhD, Yu-Hua Tseng, PhD, Kristin I. Stanford, PhD, and Anthony W. Ferrante, MD, PhD, discussed emerging understanding of how organ systems communicate to regulate and maintain energy homeostasis. Read more

Recent and emerging research sheds new light on the role of beta cells in the development and progression of type 1 diabetes. Carmella Evans-Molina, MD, PhD, explained the association between beta cell function and immune therapy efficacy. Read more

Four experts—Tammer Elmarsafi, DPM, MBBCh, Foluso Fakorede, MD, Garneisha Torrence, DPM, MHMS, and Michael D. VanPelt, DPM—discussed surgical considerations in diabetes foot management at the Scientific Sessions. Read more

Samuel Klein, MD, and Blandine Laferrère, MD, PhD, presented different viewpoints on whether the metabolic benefits of Roux-en-Y gastric bypass surgery are due to weight loss alone. Read more

Maria S. Remedi, PhD, Richard O’Brien, PhD, Aleksey Matveyenko, PhD, and Jennifer Bruin, PhD, explained several ways that diet and environmental factors can affect beta cell function, metabolic disease, and diabetes during the Scientific Sessions. Read more

A panel of investigators including Billy Tsai, PhD, Peter Thompson, MSc, PhD, Emily May Walker, PhD, and Ernesto Nakayasu, PhD, BS, discussed how emerging and ongoing research into the mechanisms of beta cell senescence is providing new insight into the roles of beta cell aging and stress in the development and progression of diabetes. Read more

Eleanor M. Scott, BM, BS, MD, FRCP, was one of five experts who addressed the utility of continuous glucose monitoring during pregnancy. A functional data analysis of two recent studies highlights the importance of tight glucose targets before the end of the first trimester for normal fetal growth, Dr. Scott said. Read more

Four researchers—Emily J. Gallagher, MD, PhD, MRCPI, M. Celeste Simon, PhD, Lydia Finley, PhD, and Marcus Goncalves, MD, MSE, PhD—looked at the connections between insulin and cancer during the Scientific Sessions. Read more

“It will be primary prevention that can be applied to a large number of the population that will really make an impact to the incident numbers of type 1 diabetes,” said Ezio Bonifacio, PhD. Read more

Wendy M. Kohrt, PhD, Karyn A. Esser, PhD, and K. Sreekumaran Nair, MD, principal investigators from the Molecular Transducers of Physical Activity Consortium, discussed how early data from animal studies is setting the stage for human studies. Read more

The pandemic exacerbated gender inequities among health care providers. In the U.S., 73% of health care providers who tested positive for COVID-19 were women. The ADA’s network for female clinicians, scientists, educators, and other health professionals discussed the impact of this and strategies to close leadership gaps. Read more

Experts in four rare forms of diabetes discussed strategies for diagnosing and treating patients with these atypical conditions during the Scientific Sessions. The session featured Janet B. McGill, MD, Marina Basina, MD, Armen Yerevanian, MD, and Mark S. Anderson, MD, PhD. Read more

A panel of physician-scientists including Ralph A. DeFronzo, MD, Chantal Mathieu, MD, PhD, Tina Vilsbøll, MD, DMSc, and David D’Alessio, MD, discussed the current evidence for combination therapies in the treatment of type 2 diabetes. Read more

Carolyn S.P. Lam, MBBS, PhD, FRCP, FAMS, FESC, FACC, Muthiah Vaduganathan, MD, MPH, Brendon Neuen, MBBS (Hons), MSc (Oxon), and David C. Wheeler, MD, FRCP, reviewed recent trial results demonstrating the safety and efficacy of SGLT2 inhibitors for both cardiovascular and renal treatment, and discussed how those trial results will help improve care for people with diabetes. Read more

Nigel A. Calcutt, PhD, Fabiana Picconi, MD, Karolina S. Khan, MD, PhD, and Kara R. Mizokami-Stout, MD, made up a panel of researchers who discussed some of the most challenging issues they face while investigating methods to prevent and treat diabetic neuropathies. Read more

Camillo Ricordi, MD, FNAI, Thierry Berney, MD, A.M. James Shapiro, MD, PhD, and Piotr Witkowski, MD, PhD, explained what has led to pancreatic islet transplantation effectively halting in the United States while the procedure has become standard of care in much of the rest of the world. Read more

“Stress is epidemic in the U.S. and other Western [countries], and most of our stressors are social,” said Carol A. Shively, PhD, in a session on the influence of social stress and social inequalities on metabolic health. She presented evidence based on animal models. Mika Kivimäki, PhD, FMedSci, presented evidence of the correlation between socioeconomic status and health. Read more

Investigators presented findings from the GRADE study comparing clinical outcomes of glimepiride, a sulfonylurea; sitagliptin, a DPP-4 inhibitor; insulin Lantus; and liraglutide, a GLP-1 receptor agonist. More than 70% of participants reached the primary metabolic endpoint. Read more

An analysis of the SCORED and SOLOIST trials favored sotagliflozin over placebo for total cardiovascular death, hospitalization for heart failure, and urgent heart failure visit. The combined SGLT1/SGLT2 inhibitor produces benefits in patients with reduced and preserved ejection fraction, said Deepak Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC. Read more

“The road ahead for the treatment of type 2 diabetes is fresh," said Alice Y.Y. Cheng, MD. "The future, in terms of what we will be able to offer our patients to help them meet their metabolic goals, appears to be very positive.” Read more

The efficacy and safety outcomes of efpeglenatide are similar to the outcomes seen in trials of other GLP-1 receptor agonists, according to researchers who presented AMPLITUDE-O data at the Scientific Sessions. Read more

DARE-19 was the first large, randomized clinical trial of an SGLT2 inhibitor to address the potential benefits of these agents in patients hospitalized with COVID-19. Results showed no significant effect on organ failure or survival. Mikhail N. Kosiborod, MD, was the principal investigator. Read more

Before finalizing the first-ever ADA/EASD Consensus Report on the management of adults with type 1 diabetes, the writing team led by Anne L. Peters, MD, and Richard I.G. Holt, PhD, FRCP, highlighted key topics addressed in the report at the Scientific Sessions. Read more

Kristen J. Nadeau, MD, MS, outlined the unique cardiometabolic mechanisms and consequences of youth-onset type 1 and type 2 diabetes in her award lecture. Read more

An infectious disease epidemiologist, a journalist, and a researcher—Christina M. Astley, MD, ScD, Gary Schwitzer, and Bertha Hidalgo, PhD, MPH—came together to share their perspectives on communication of risk and its impact on public health and public trust. Read more

An international panel of diabetes prevention researchers including Mike Sampson, MD, Kerri Lynn Knippen, PhD, MPH, RDN, LD, BC-ADM, Pilvikki Absetz, PhD, and Anne M. Wolf, MS, RDN, shared lessons learned from the implementation of type 2 diabetes prevention programs around the world during a symposium Monday. Read more

“We know there are so many people who are getting suboptimal care in terms of diabetes—inpatient and outpatient—because we can’t reach them all. We really need to use technology as a base," said Amisha Wallia, MD, MS. Read more

The story of incretins began in the gut—and then something happened, said Jens Juul Holst, MD, DrMedSci. Islets and the pancreas developed from the gut and remain connected by gut hormones, he noted. Read more

As an early-career scientist, Nicholas J. Wareham, FMedSci, FRCP, FFPHM, MBBS, MSc, PhD, developed a strong interest in diabetes screening and was fascinated by then-emerging details of the links between risk factors and type 2 diabetes. Read more

“One of the lessons from the discovery of insulin is to remind us how important it is for us to support high-risk innovative ideas, new and junior investigators—in addition to more established investigators—and basic, clinical, and translational research,” said ADA President, Medicine & Science, Ruth S. Weinstock, MD, PhD. Read more

“The central nervous system is an important target organ for GLP-1 and GIP pharmacotherapy to affect energy balance,” said Alice Adriaenssens, PhD, in the ADA Diabetes Symposium. Read more

David G. Marrero, PhD, advocated for a social-ecological model to better understand and integrate diabetes care in a symposium focused on preserving mental health across the lifespan of living with this disease. Read more

Kelly M. Rawlings, MS, and Marci Butcher, RD, LN, CDCES, FADCES, will discuss digital health and diabetes support in a two-hour symposium Monday afternoon. Read more

Maureen Monaghan, PhD, CDCES, Samantha Kleinberg, PhD, and Jennifer Raymond, MD, MCR, will offer insight into navigating the diabetes digital landscape. Read more

An expert panel including Kathryn Haskins, PhD, Teresa P. DiLorenzo, PhD, and Megan K. Levins, PhD, will discuss the past, present, and future of T cells in diabetes treatment. Read more

Carlos A. Monteiro, MD, PhD, will share data on the effects of ultraprocessed foods, while Sung Kyun Park, ScD, MPH, will provide data on per- and polyfluoroalkyl substances. Read more

Raghavendra Rao, MD, Charles Stanley, MD, Sarbattama Sen, MD, and Paul Rozance, MD, will address whether neonatal hypoglycemia is overdiagnosed or underestimated in this symposium. Read more

A joint symposium of the ADA and the International Society for Pediatric and Adolescent Diabetes featuring Richard A. Oram, MD, PhD, and R. Brett McQueen, PhD, will consider general population screening versus targeted screening. Read more

The data from continuous glucose monitoring devices can help patients make more informed decisions on lifestyle modifications, insulin dosing, and meal planning. Thomas W. Martens, MD, Dana Gershenoff, MS, RD, CDCES, and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, explain how. Read more

In her address Saturday, ADA President, Health Care & Education, Cynthia E. Muñoz, PhD, MPH, discussed how the ADA is addressing systemic health care disparities among children with diabetes. Read more

Award recipient Denise Charron-Prochownik, PhD, RN, CPNP, recounted the 30-year history of Reproductive-health Education and Awareness of Diabetes in Youth for Girls. The program reinforces health care provider education and counseling. Read more

The ADA Diabetes Care Symposium, with speakers Edward W. Gregg, PhD, and Linda DiMeglio, MD, MPH, focused on minimizing risks for people with diabetes during the pandemic. This population accounts for 30% to 40% of hospitalized COVID-19 patients. Read more

Brian V. Burke, MD, FACP, Mary M. Julius, RDN, LD, CDCES, Stephanie De Leon Ansley, MS, RD, CSSD, LD, CDCES, and Brian James, MEd, explained how this avatar-to-avatar DSMES program operates. Read more

Jerome F. Strauss III, MD, PhD, Erik A. Richter, MD, DMSci, Karen Elkind-Hirsch, MS, PhD, and Anuja Dokras, MD, PhD, reviewed advances in the diagnosis and care of women with polycystic ovary syndrome. Read more

Catlin Dennis, MPH, Gretchen Piatt, PhD, MPH, Christine H. Wang, PhD, and Sarah Westen, PhD, will come together to help quantify the toll the COVID-19 pandemic has taken on diabetes patients and their families. Read more

Data support the use of telehealth and remote monitoring for patients with diabetes. Leslie A. Eiland, MD, Lindsay S. Mayberry, PhD, MS, and Irl B. Hirsch, MD, outline how to use these tools for different populations. Read more

The symposium will include a review of treatment options for preproliferative diabetic retinopathy by Jennifer Sun, MD, MPH, and an overview of advancements in retinal neurovascular degeneration in diabetes by Patrice E. Fort, PhD, MS. Read more

“The understanding of energy metabolism and its relation to diabetes and obesity is undergoing a revolution,” said Bruce Spiegelman, PhD, one of the researchers who will discuss emerging paradigms of uncoupled bioenergentics in metabolic disease. Read more

Some type 1 diabetes trials that were suspended last year because of COVID-19 have resumed. Carla Greenbaum, MD, and Adriana Weinberg, MD, debated whether such studies should have restarted while the pandemic is ongoing. Read more

Brian M. Schmidt, DPM, and Laura Shin, DPM, PhD, shared strategies used to maintain access to care and regular physical exams for patients with diabetic foot complications amid COVID-19. Read more

Emilyn Uy Alejandro, PhD, and Rochelle N. Naylor, MD, will discuss new insight into the heterogeneity of diabetes and how it translates to patient care. Read more

Yehuda Handelsman, MD, Tina Costacou, PhD, and Sophia Zoungas, MBBS (Hons), PhD, FRACP, will examine the dynamics of weight and cardiovascular risk in type 1 diabetes. The symposium includes a debate on drugs to prevent cardiovascular disease. Read more

“You could eat a diet of bacon and diet soda all day long and you’d manage your glucose really well. But that wouldn’t be good for your whole health,” said Holly Willis, PhD, RDN, LD. Read more

Hui Shao, MD, PhD, will discuss the financial implications these classes of agents, which have transformed diabetes care for individuals who also have cardiovascular disease, have brought to the health care system. Read more

Shivani Agarwal, MD, MPH, Shakira Suglia, ScD, MS, and J. Frank Wharam, MD, MPH, will examine strategies to address risks influenced by social needs and to improve outcomes. Read more

The digital diabetes care market will be worth upward of $700 million in 2022. Anne L. Peters, MD, and Kasia J. Lipska, MD, MHS, BS, will explore whether it is worth the cost. Read more

Jennifer Sherr, MD, PhD, will highlight new glucagon formulations for treatment, and Nicole de Zoysa, DClinPsych, will review the impact of overcoming psychological obstacles on optimal hypoglycemia management. Read more

The average ages of patients who are potentially eligible for pancreas transplantation and of potential organ donors are on the rise, but that is not the only challenge for this sector of the diabetes community, as Eelco J.P. de Koning, MD, PhD, will explain. Read more

A combined SGLT1/SGLT2 inhibitor may be the next addition to the armamentarium of drugs for patients with diabetes. Deepak Bhatt, MD, MPH, will explain why and take a comprehensive look at data from recent clinical trials of sotagliflozin. Read more

Hertzel C. Gerstein, MD, MSc, FRCPC, will offer insight into the use of an exendin-based GLP-1 receptor agonist in people with type 2 diabetes and high cardiovascular risk. Read more

Richard I.G. Holt, PhD, FRCP, and Anne L. Peters, MD, and their writing team will summarize the key topics addressed by this trans-Atlantic collaboration. Read more